<DOC>
	<DOCNO>NCT00442169</DOCNO>
	<brief_summary>The purpose study determine whether single subcutaneous injection ChimeriVax-WN02 vaccine well tolerate , safe induces protective antibody West Nile Disease . The study divide two part ; first part , comparison 3 dose level vaccine make , inactive control . In second part , optimum dose level choose first part give old volunteer .</brief_summary>
	<brief_title>Safety Immunogenicity ChimeriVax-WN02 West Nile Vaccine Healthy Adults</brief_title>
	<detailed_description>West Nile Disease carry across United States migrate bird since first identify New York city 1999 . It transmit mosquito bird human cause severe disease individual . There specific treatment West Nile Disease . The target population West Nile vaccine old people , susceptible severe disease . This trial include dose-finding part placebo control young healthy adult , follow placebo-controlled examination choose dose old healthy adult . Outcome measure include comparison adverse event active treatment placebo , comparison antibody viremia measurement dose level across age group dose choose Part 2 .</detailed_description>
	<mesh_term>West Nile Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Part 1 Healthy adult age 18 40 year . Women childbearing potential use hormonal contraception . Subject available study duration , include plan followup visit . Part 1 Previous vaccination yellow fever Japanese encephalitis History flavivirus infection Any abnormality immune system , use drug affect immune system . History anaphylaxis food , bee sting , vaccine drug . Receipt blood blood product within precede 6 month . Receipt vaccine precede 30 day Seropositive hepatitis C virus ( HCV ) , hepatitis B surface antigen ( HBsAg ) Human immunodeficiency virus ( HIV ) Lactation intend pregnancy female subject Previous current military service overseas deployment Travel Mexico flavivirus endemic area tropic period four week previous ten year . Part 2 Aged ≥ 41 year . Subjects general good health . Unimpaired cognitive performance assess clock draw test score Subject available require study visit , include plan followup visit . Women childbearing potential use hormonal contraception . Part 2 Clinically significant abnormality Screening 12lead electrocardiogram ( ECG ) . An acute chronic medical condition , opinion Investigator , would render vaccination unsafe would interfere evaluation response . These condition include , limited : History renal impairment History significant liver disease hepatic impairment History diabetes mellitus ( except control diet ) An arteriosclerotic event 6 month prior enrollment ( include limit myocardial infarction unstable angina , peripheral bypass surgery revascularization extremity , transient ischemic attack stroke ) Signs congestive heart failure time enrollment Angina Subjects 3 following : Age 50 year Hypercholesterolemia , significantly abnormal lipid profile , base medical history Any prior history cardiovascular disease Significant family history cardiovascular disease immediate relative History significant collagen vascular disease . The unexplained presence follow finding : Any significant episode confusion , memory loss , language impairment , cognitive impairment , abnormal behavior relatively abrupt onset Clinically significant depression Sudden visual impairment ( e.g. , loss vision , double vision ) Slurred abnormal speech Sudden onset vertigo Focal weakness extremity Focal sensory loss extremity Impaired balance Impaired gait . Subjects diagnosis dementia associate concomitant medication ( e.g. , Aricept ) use treat dementia . Subjects active history neurologic disease injury , include , limited : Parkinson 's , Guillain Barre , epilepsy ( except febrile seizure youth treated medication ) , cerebrovascular accident , head trauma , neurologic condition think impact integrity bloodbrain barrier . Subjects take warfarin , heparin , know bleeding disorder . Relative employee study site staff , CRO , Sponsor participate trial . A history vaccination yellow fever ( YF ) Japanese encephalitis . Previous vaccination determine history ( interview subject ) and/or review subject 's vaccination card official documentation . History flavivirus infection ( e.g . West Nile [ WN ] , Systemic Lupus Erythematosus [ SLE ] , Japanese encephalitis , dengue fever ) . History thymoma , thymic surgery ( removal ) , myasthenia gravis . Known suspected immunodeficiency disorder , include leukemia , lymphoma , generalized malignancy , treatment immunosuppressive medication , include corticosteroid , alkylating agent , antimetabolite , radiation therapy . Low dose steroid ( ≤ 10 mg prednisone equivalent , topical intra articular/bursal/tendon/epidural injection corticosteroid ) constitute reason exclusion . History residence travel Mexico flavivirus endemic area tropic ( India , southeast Asia , Central America , Caribbean , South America ) periods 4 week within last 10 year . Subjects clinically significant screen laboratory abnormality and/or follow : Compromised hematopoietic function define hemoglobin &lt; 10.9 ( male ) 9.4 ( female ) g/dL ; lymphocyte count &gt; 3000 mm3 ; neutrophil count &lt; 1000 mm3 ; platelet count &lt; 100,000 mm3 . Hepatic dysfunction define bilirubin upper limit normal aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal . Prior history anaphylaxis food , hymenoptera sting , vaccine , drug . Transfusion blood treatment blood product , include intramuscular intravenous serum globulin within 6 month Screening Visit anticipate Day 28 , intention donate blood 28 day vaccination . Administration another vaccine within 30 day precede screen visit anticipate Day 28 ( subject could reschedule vaccination later date ) . Physical examination indicate clinically significant medical condition . Subjects body temperature &gt; 37.8ºC/100.0ºF acute illness within 3 day prior vaccination ( subject could reschedule ) . Intention travel area prior study visit Day 28 , require study visit would miss . Seropositive HCV HIV positive HBsAg . Participation another clinical trial within 60 day Screening . Lactation intend pregnancy female subject . History excessive alcohol consumption , drug abuse , significant psychiatric illness . Intention increase normal exercise routine , participate contact sport strenuous weight lifting , initiate vigorous exercise Screening Day 28 . At time study past military service overseas deployment within 10 year screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>West Nile Disease</keyword>
	<keyword>Antibody response</keyword>
	<keyword>Viremia</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Prevention</keyword>
</DOC>